Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

July 31, 2008

Conditions
Cystic Fibrosis
Interventions
DRUG

inhaled 7% hypertonic saline (HS)

"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"

Trial Locations (3)

98105

Children's Hospital and Regional Medical Center, Seattle

27599-7248

University of North Carolina, Chapel Hill

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

CF Therapeutics Development Network Coordinating Center

NETWORK

NCT00546663 - Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis | Biotech Hunter | Biotech Hunter